Dysregulated expression of glycolipids in tumor cells: From Negative Modulator of Anti-tumor Immunity to Promising Targets for Developing Therapeutic Agents

Frontiers in Oncology

Volumn 5, Issue JAN, 2016, Pages

  Daniotti, Jose Luis ^a   Lardone, Ricardo D ^b   Vilcaes, Aldo A ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

Antibodies; Cancer; Gangliosides; Glycolipids; Immunotherapy; Immunotoxin

Indexed keywords

GAMMA INTERFERON; GLYCOLIPID; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; RACOTUMOMAB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNOTHERAPY; CARBOHYDRATE SYNTHESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NONHUMAN; ONTOGENY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SHORT SURVEY; TUMOR GROWTH; UPREGULATION;

EID: 84958175805     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00300     Document Type: Short Survey

References (153)

1. Crespo PM, Demichelis VT, Daniotti JL. Neobiosynthesis of glycosphingolipids by plasma membrane-associated glycosyltransferases. J Biol Chem (2010) 285(38):29179-90. doi: 10.1074/jbc. M110.123422
2. Vilcaes AA, Demichelis VT, Daniotti JL. Trans-activity of plasma membrane-associated ganglioside sialyltransferase in mammalian cells. J Biol Chem (2011) 286(36):31437-46. doi:10.1074/jbc. M111.257196
3. Iwamori M, Iwamori Y. Changes in the glycolipid composition and characteristic activation of GM3 synthase in the thymus of mouse after administration of dexamethasone. Glycoconj J (2005) 22(3):119-26. doi:10.1007/s10719-005-0363-9
4. Yogeeswaran G, Laine RA, Hakomori S. Mechanism of cell contact-dependent glycolipid synthesis: further studies with glycolipid-glass complex. Biochem Biophys Res Commun (1974) 59(2):591-9. doi:10.1016/S0006-291X(74)80021-5
5. Daniotti JL, Iglesias-Bartolome R. Metabolic pathways and intracellular trafficking of gangliosides. IUBMB Life (2011) 63(7):513-20. doi:10.1002/iub.477
6. Hanada K, Kumagai K, Yasuda S, Miura Y, Kawano M, Fukasawa M, et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature (2003) 426(6968):803-9. doi:10.1038/nature02188
7. Maccioni HJ, Quiroga R, Ferrari ML. Cellular and molecular biology of glycosphingolipid glycosylation. J Neurochem (2011) 117(4):589-602. doi:10.1111/j.1471-4159.2011.07232.x
8. Merrill AH Jr. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev (2011) 111(10):6387-422. doi:10.1021/cr2002917
9. Tettamanti G. Ganglioside/glycosphingolipid turnover: new concepts. Glycoconj J (2004) 20(5):301-17. doi:10.1023/B:GLYC.0000033627.02765.cc
10. Mencarelli S, Cavalieri C, Magini A, Tancini B, Basso L, Lemansky P, et al. Identification of plasma membrane associated mature beta-hexosaminidase A, active towards GM2 ganglioside, in human fibroblasts. FEBS Lett (2005) 579(25):5501-6. doi:10.1016/j.febslet.2005.08.081
11. Miyagi T, Yamaguchi K. Mammalian sialidases: physiological and pathological roles in cellular functions. Glycobiology (2012) 22(7):880-96. doi:10.1093/glycob/cws057
12. Prinetti A, Chigorno V, Mauri L, Loberto N, Sonnino S. Modulation of cell functions by glycosphingolipid metabolic remodeling in the plasma membrane. J Neurochem (2007) 103:113-25. doi:10.1111/j.1471-4159.2007.04714.x
13. Rodriguez-Walker M, Vilcaes AA, Garbarino-Pico E, Daniotti JL. Role of plasma-membrane-bound sialidase NEU3 in clathrin-mediated endocytosis. Biochem J (2015) 470(1):131-44. doi:10.1042/BJ20141550
14. Sonnino S, Aureli M, Loberto N, Chigorno V, Prinetti A. Fine tuning of cell functions through remodeling of glycosphingolipids by plasma membrane-associated glycohydrolases. FEBS Lett (2010) 584(9):1914-22. doi:10.1016/j.febslet.2009.11.020
15. Kolter T. Ganglioside biochemistry. ISRN Biochem (2012) 2012:506160. doi:10.5402/2012/506160
16. Kolter T, SandhoffK. Lysosomal degradation of membrane lipids. FEBS Lett (2010) 584(9):1700-12. doi:10.1016/j.febslet.2009.10.021
17. SandhoffK, Kolter T. Biosynthesis and degradation of mammalian glycosphingolipids. Philos Trans R Soc Lond B Biol Sci (2003) 358(1433):847-61. doi:10.1098/rstb.2003.1265
18. Daniotti JL, Vilcaes AA, Torres Demichelis V, Ruggiero FM, Rodriguez-Walker M. Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approaches. Front Oncol (2013) 3:306. doi:10.3389/fonc.2013.00306
19. Hakomori S. Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. Annu Rev Biochem (1981) 50:733-64. doi:10.1146/annurev.bi.50.070181.003505
20. Maccioni HJ. Glycosylation of glycolipids in the Golgi complex. J Neurochem (2007) 103:81-90. doi:10.1111/j.1471-4159.2007.04717.x
21. Maccioni HJ, Daniotti JL, Martina JA. Organization of ganglioside synthesis in the Golgi apparatus. Biochim Biophys Acta (1999) 1437(2):101-18. doi:10.1016/S1388-1981(99)00002-5
22. Daniotti JL, Crespo PM, Yamashita T. In vivo modulation of epidermal growth factor receptor phosphorylation in mice expressing different gangliosides. J Cell Biochem (2006) 99(5):1442-51. doi:10.1002/jcb.21034
23. Lopez PH, Schnaar RL. Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol (2009) 19(5):549-57. doi:10.1016/j.sbi.2009.06.001
24. Proia RL. Glycosphingolipid functions: insights from engineered mouse models. Philos Trans R Soc Lond B Biol Sci (2003) 358(1433):879-83. doi:10.1098/rstb.2003.1268
25. Regina Todeschini A, Hakomori SI. Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains. Biochim Biophys Acta (2008) 1780(3):421-33. doi:10.1016/j.bbagen.2007.10.008
26. Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, Norton A, et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci U S A (2003) 100(6):3445-9. doi:10.1073/pnas.0635898100
27. Ziulkoski AL, Andrade CM, Crespo PM, Sisti E, Trindade VM, Daniotti JL, et al. Gangliosides of myelosupportive stroma cells are transferred to myeloid progenitors and are required for their survival and proliferation. Biochem J (2006) 394(Pt 1):1-9. doi:10.1042/BJ20051189
28. Zurita AR, Maccioni HJ, Daniotti JL. Modulation of epidermal growth factor receptor phosphorylation by endogenously expressed gangliosides. Biochem J (2001) 355(Pt 2):465-72. doi:10.1042/0264-6021:3550465
29. d'Azzo A, Bonten E. Molecular mechanisms of pathogenesis in a glycosphingolipid and a glycoprotein storage disease. Biochem Soc Trans (2010) 38(6):1453-7. doi:10.1042/BST0381453
30. Kolter T, SandhoffK. Sphingolipid metabolism diseases. Biochim Biophys Acta (2006) 1758(12):2057-79. doi:10.1016/j.bbamem.2006.05.027
31. Platt FM. Sphingolipid lysosomal storage disorders. Nature (2014) 510(7503):68-75. doi:10.1038/nature13476
32. Harlalka GV, Lehman A, Chioza B, Baple EL, Maroofian R, Cross H, et al. Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis. Brain (2013) 136(Pt 12):3618-24. doi:10.1093/brain/awt270
33. Hu H, Eggers K, Chen W, Garshasbi M, Motazacker MM, Wrogemann K, et al. ST3GAL3 mutations impair the development of higher cognitive functions. Am J Hum Genet (2011) 89(3):407-14. doi:10.1016/j.ajhg.2011.08.008
34. Simpson MA, Cross H, Proukakis C, Priestman DA, Neville DC, Reinkensmeier G, et al. Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet (2004) 36(11):1225-9. doi:10.1038/ng1460
35. Kloppel TM, Keenan TW, Freeman MJ, Morré DJ. Glycolipid-bound sialic acid in serum: increased levels in mice and humans bearing mammary carcinomas. Proc Natl Acad Sci U S A (1977) 74(7):3011-3. doi:10.1073/pnas.74.7.3011
36. Lauc G, Heffer-Lauc M. Shedding and uptake of gangliosides and glycosylphosphatidylinositol-anchored proteins. Biochim Biophys Acta (2006) 1760(4):584-602. doi:10.1016/j.bbagen.2005.11.014
37. Olshefski R, Ladisch S. Intercellular transfer of shed tumor cell gangliosides. FEBS Lett (1996) 386(1):11-4. doi:10.1016/0014-5793(96)00392-4
38. Portoukalian J, Zwingelstein G, Abdul-Malak N, Doré JF. Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors. Biochem Biophys Res Commun (1978) 85(3):916-20. doi:10.1016/0006-291X(78)90630-7
39. Lardone RD, Cely I, Sieling PA, Lee DJ. Immune response modulation by tumor-secreted glycosphingolipids. J Glycobiol (2014) 3(1):107. doi:10.4172/2168-958X.1000107
40. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 121(1):1-14. doi:10.1111/j.1365-2567.2007.02587.x
41. Boligan KF, Mesa C, Fernandez LE, von Gunten S. Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense. Cell Mol Life Sci (2015) 72(7):1231-48. doi:10.1007/s00018-014-1799-5
42. Andreesen R, Osterholz J, Bross KJ, Schulz A, Luckenbach GA, Löhr GW. Cytotoxic effector cell function at different stages of human monocyte-macrophage maturation. Cancer Res (1983) 43(12 Pt 1):5931-6.
43. Lefebvre ML, Krause SW, Salcedo M, Nardin A. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother (2006) 29(4):388-97. doi:10.1097/01.cji.0000203081.43235.d7
44. Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol (2008) 181(9):5829-35. doi:10.4049/jimmunol.181.9.5829
45. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, et al. NK cells and cancer. J Immunol (2007) 178(7):4011-6. doi:10.4049/jimmunol.178.7.4011
46. Porcelli SA, Modlin RL. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol (1999) 17(1):297-329. doi:10.1146/annurev.immunol.17.1.297
47. Lee AF, Sieling PA, Lee DJ. Immune correlates of melanoma survival in adoptive cell therapy. Oncoimmunology (2013) 2(2):e22889. doi:10.4161/onci.22889
48. Heitger A, Ladisch S. Gangliosides block antigen presentation by human monocytes. Biochim Biophys Acta (1996) 1303(2):161-8. doi:10.1016/0005-2760(96)00091-4
49. Caldwell S, Heitger A, Shen W, Liu Y, Taylor B, Ladisch S. Mechanisms of ganglioside inhibition of APC function. J Immunol (2003) 171(4):1676-83. doi:10.4049/jimmunol.171.4.1676
50. Ziegler-Heitbrock HW, Käfferlein E, Haas JG, Meyer N, Ströbel M, Weber C, et al. Gangliosides suppress tumor necrosis factor production in human monocytes. J Immunol (1992) 148(6):1753-8.
51. Hoon DS, Jung T, Naungayan J, Cochran AJ, Morton DL, McBride WH. Modulation of human macrophage functions by gangliosides. Immunol Lett (1989) 20(4):269-75. doi:10.1016/0165-2478(89)90034-5
52. Shen W, Stone K, Jales A, Leitenberg D, Ladisch S. Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides. J Immunol (2008) 180(7):4425-32. doi:10.4049/jimmunol.180.7.4425
53. Kim SJ, Chung TW, Choi HJ, Jin UH, Ha KT, Lee YC, et al. Monosialic ganglioside GM3 specifically suppresses the monocyte adhesion to endothelial cells for inflammation. Int J Biochem Cell Biol (2014) 46:32-8. doi:10.1016/j.biocel.2013.09.015
54. Wondimu A, Liu Y, Su Y, Bobb D, Ma JS, Chakrabarti L, et al. Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells. Cancer Res (2014) 74(19):5449-57. doi:10.1158/0008-5472.CAN-14-0927
55. WölflM, Batten WY, Posovszky C, Bernhard H, Berthold F. Gangliosides inhibit the development from monocytes to dendritic cells. Clin Exp Immunol (2002) 130(3):441-8. doi:10.1046/j.1365-2249.2002.02006.x
56. Shen W, Falahati R, Stark R, Leitenberg D, Ladisch S. Modulation of CD4 Th cell differentiation by ganglioside GD1a in vitro. J Immunol (2005) 175(8):4927-34. doi:10.4049/jimmunol.175.8.4927
57. Péguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol (2003) 170(7):3488-94. doi:10.4049/jimmunol.170.7.3488
58. Bennaceur K, Popa I, Chapman JA, Migdal C, Péguet-Navarro J, Touraine JL, et al. Different mechanisms are involved in apoptosis induced by melanoma gangliosides on human monocyte-derived dendritic cells. Glycobiology (2009) 19(6):576-82. doi:10.1093/glycob/cwp015
59. Bennaceur K, Popa I, Portoukalian J, Berthier-Vergnes O, Péguet-Navarro J. Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int Immunol (2006) 18(6):879-86. doi:10.1093/intimm/dxl024
60. Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Démoulins T, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest (2014) 124(4):1810-20. doi:10.1172/JCI65899
61. Kawasaki Y, Ito A, Withers DA, Taima T, Kakoi N, Saito S, et al. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells. Glycobiology (2010) 20(11):1373-9. doi:10.1093/glycob/cwq116
62. Nicoll G, Avril T, Lock K, Furukawa K, Bovin N, Crocker PR. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and-independent mechanisms. Eur J Immunol (2003) 33(6):1642-8. doi:10.1002/eji.200323693
63. Webb TJ, Li X, Giuntoli RL II, Lopez PH, Heuser C, Schnaar RL, et al. Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res (2012) 72(15):3744-52. doi:10.1158/0008-5472.CAN-11-2695
64. Sriram V, Cho S, Li P, O'Donnell PW, Dunn C, Hayakawa K, et al. Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells. Proc Natl Acad Sci U S A (2002) 99(12):8197-202. doi:10.1073/pnas.122636199
65. Kimata H, Yoshida A. Differential effects of gangliosides on Ig production and proliferation by human B cells. Blood (1994) 84(4):1193-200.
66. Kimata H, Yoshida A. Inhibition of spontaneous immunoglobulin production by ganglioside GM2 in human B cells. Clin Immunol Immunopathol (1996) 79(2):197-202. doi:10.1006/clin.1996.0068
67. Kanda N, Tamaki K. Ganglioside GD1b suppresses immunoglobulin production by human peripheral blood mononuclear cells. Exp Hematol (1999) 27(10):1487-93. doi:10.1016/S0301-472X(99)00093-4
68. Kanda N, Tamaki K. Ganglioside GT1b suppresses immunoglobulin production by human peripheral blood mononuclear cells. Immunology (1999) 96(4):628-33. doi:10.1046/j.1365-2567.1999.00734.x
69. Kanda N, Tamaki K. Ganglioside GQ1b enhances Ig production by human PBMCs. J Allergy Clin Immunol (1998) 102(5):813-20. doi:10.1016/S0091-6749(98)70022-3
70. Kanda N, Watanabe S. Ganglioside GD1a enhances immunoglobulin production by human peripheral blood mononuclear cells. Exp Hematol (2000) 28(6):672-9. doi:10.1016/S0301-472X(00)00167-3
71. Zhou J, Shao H, Cox NR, Baker HJ, Ewald SJ. Gangliosides enhance apoptosis of thymocytes. Cell Immunol (1998) 183(2):90-8. doi:10.1006/cimm.1998.1247
72. Inokuchi J, Nagafuku M, Ohno I, Suzuki A. Distinct selectivity of gangliosides required for CD4(+) T and CD8(+) T cell activation. Biochim Biophys Acta (2015) 1851(1):98-106. doi:10.1016/j.bbalip.2014.07.013
73. Nakamori M, Iwahashi M, Nakamura M, Ueda K, Zhang X, Yamaue H. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer. Clin Cancer Res (2003) 9(6):2357-65.
74. Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M, et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol (1999) 163(9):5020-8.
75. Pellegrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother (1996) 42(1):1-8. doi:10.1007/s002620050244
76. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol (1994) 12(1):141-79. doi:10.1146/annurev.iy.12.040194.001041
77. Uzzo RG, Rayman P, Kolenko V, Clark PE, Cathcart MK, Bloom T, et al. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest (1999) 104(6):769-76. doi:10.1172/JCI6775
78. Thornton MV, Kudo D, Rayman P, Horton C, Molto L, Cathcart MK, et al. Degradation of NF-κB in T cells by gangliosides expressed on renal cell carcinomas. J Immunol (2004) 172(6):3480-90. doi:10.4049/jimmunol.172.6.3480
79. Crespo FA, Sun X, Cripps JG, Fernandez-Botran R. The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses. J Leukoc Biol (2006) 79(3):586-95. doi:10.1189/jlb.0705395
80. Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G, et al. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res (2004) 10(18 Pt 2):6360S-6S. doi:10.1158/1078-0432.CCR-050011
81. Irani DN, Lin KI, Griffin DE. Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J Immunol (1996) 157(10):4333-40.
82. Biswas S, Biswas K, Richmond A, Ko J, Ghosh S, Simmons M, et al. Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol (2009) 183(8):5050-8. doi:10.4049/jimmunol.0900259
83. Kudo D, Rayman P, Horton C, Cathcart MK, Bukowski RM, Thornton M, et al. Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells. Cancer Res (2003) 63(7):1676-83.
84. Sa G, Das T, Moon C, Hilston CM, Rayman PA, Rini BI, et al. GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res (2009) 69(7):3095-104. doi:10.1158/0008-5472.CAN-08-3776
85. Mahata B, Biswas S, Rayman P, Chahlavi A, Ko J, Bhattacharjee A, et al. GBM derived gangliosides induce T cell apoptosis through activation of the caspase cascade involving both the extrinsic and the intrinsic pathway. PLoS One (2015) 10(7):e0134425. doi:10.1371/journal.pone.0134425
86. Raval G, Biswas S, Rayman P, Biswas K, Sa G, Ghosh S, et al. TNF-alpha induction of GM2 expression on renal cell carcinomas promotes T cell dysfunction. J Immunol (2007) 178(10):6642-52. doi:10.4049/jimmunol.178.10.6642
87. Chu JW, Sharom FJ. Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors. Immunology (1993) 79(1):10-7.
88. McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol (1999) 163(7):3718-26.
89. Lee HC, Wondimu A, Liu Y, Ma JS, Radoja S, Ladisch S. Ganglioside inhibition of CD8+ T cell cytotoxicity: interference with lytic granule trafficking and exocytosis. J Immunol (2012) 189(7):3521-7. doi:10.4049/jimmunol.1201256
90. Lo AS, Ma Q, Liu DL, Junghans RP. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res (2010) 16(10):2769-80. doi:10.1158/1078-0432.CCR-10-0043
91. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin (1996) 46(4):225-44. doi:10.3322/canjclin.46.4.225
92. Nores GA, Dohi T, Taniguchi M, Hakomori S. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J Immunol (1987) 139(9):3171-6.
93. Cheresh DA, Rosenberg J, Mujoo K, Hirschowitz L, Reisfeld RA. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res (1986) 46(10):5112-8.
94. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (1997) 73(1):42-9. doi:10.1002/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1
95. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A (2003) 100(21):12045-50. doi:10.1073/pnas.2131556100
96. Nguyen DH, Tangvoranuntakul P, Varki A. Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells. J Immunol (2005) 175(1):228-36. doi:10.4049/jimmunol.175.1.228
97. Tokuda N, Zhang Q, Yoshida S, Kusunoki S, Urano T, Furukawa K, et al. Genetic mechanisms for the synthesis of fucosyl GM1 in small cell lung cancer cell lines. Glycobiology (2006) 16(10):916-25. doi:10.1093/glycob/cwl022
98. Horwacik I, Rokita H. Targeting of tumor-associated gangliosides with antibodies affects signaling pathways and leads to cell death including apoptosis. Apoptosis (2015) 20(5):679-88. doi:10.1007/s10495-015-1103-7
99. Hakomori SI, Handa K. GM3 and cancer. Glycoconj J (2015) 32(1-2):1-8. doi:10.1007/s10719-014-9572-4
100. Kieber-Emmons T, Saha S, Pashov A, Monzavi-Karbassi B, Murali R. Carbohydrate-mimetic peptides for pan anti-tumor responses. Front Immunol (2014) 5:308. doi:10.3389/fimmu.2014.00308
101. Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett (2014) 588(2):288-97. doi:10.1016/j.febslet.2013.11.030
102. Gómez RE, Ardigo ML. Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective. Front Oncol (2012) 2:147. doi:10.3389/fonc.2012.00147
103. Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res (1997) 7:S155-62. doi:10.1097/00008390-199708001-00024
104. Ravindranath MH, Morton DL. Role of gangliosides in active immunotherapy with melanoma vaccine. Int Rev Immunol (1991) 7(4):303-29. doi:10.3109/08830189109114877
105. Slovin SF, Keding SJ, Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol (2005) 83(4):418-28. doi:10.1111/j.1440-1711.2005.01350.x
106. Gilbert ER, Eby JM, Hammer AM, Klarquist J, Christensen DG, Barfuss AJ, et al. Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis. Am J Pathol (2013) 183(1):226-34. doi:10.1016/j.ajpath.2013.04.002
107. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med (1982) 155(4):1133-47. doi:10.1084/jem.155.4.1133
108. Iglesias-Bartolomé R, Crespo PM, Gomez GA, Daniotti JL. The antibody to GD3 ganglioside, R24, is rapidly endocytosed and recycled to the plasma membrane via the endocytic recycling compartment. Inhibitory effect of brefeldin A and monensin. FEBS J (2006) 273(8):1744-58. doi:10.1111/j.1742-4658.2006.05194.x
109. Torres Demichelis V, Vilcaes AA, Iglesias-Bartolomé R, Ruggiero FM, Daniotti JL. Targeted delivery of immunotoxin by antibody to ganglioside GD3: a novel drug delivery route for tumor cells. PLoS One (2013) 8(1):e55304. doi:10.1371/journal.pone.0055304
110. Higgins SC, Fillmore HL, Ashkan K, Butt AM, Pilkington GJ. Dual targeting NG2 and GD3A using Mab-Zap immunotoxin results in reduced glioma cell viability in vitro. Anticancer Res (2015) 35(1):77-84.
111. Guillemard V, Saragovi HU. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res (2001) 61(2):694-9.
112. Guillemard V, Uri Saragovi H. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene (2004) 23(20):3613-21. doi:10.1038/sj.onc.1207463
113. Gajdosik Z. Racotumomab-a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer. Drugs Today (Barc) (2014) 50(4):301-7. doi:10.1358/dot.2014.50.4.2116670
114. Alfonso S, Valdés-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernández M, et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res (2014) 20(14):3660-71. doi:10.1158/1078-0432.CCR-13-1674
115. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 363(14):1324-34. doi:10.1056/NEJMoa0911123
116. Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol (2014) 32(14):1445-52. doi:10.1200/JCO.2013.50.4423
117. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol (2010) 28(33):4969-75. doi:10.1200/JCO.2009.27.8861
118. Albertini MR, Hank JA, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, et al. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunol Immunother (2012) 61(12):2261-71. doi:10.1007/s00262-012-1286-5
119. Young PA, Morrison SL, Timmerman JM. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. Semin Oncol (2014) 41(5):623-36. doi:10.1053/j.seminoncol.2014.08.002
120. Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, et al. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med (2012) 16(3):569-81. doi:10.1111/j.1582-4934.2011.01343.x
121. Lode HN, Schmidt M, Seidel D, Huebener N, Brackrock D, Bleeke M, et al. Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response. Cancer Immunol Immunother (2013) 62(6):999-1010. doi:10.1007/s00262-013-1413-y
122. Kwon HY, Kim SJ, Kim CH, Son SW, Kim KS, Lee JH, et al. Triptolide downregulates human GD3 synthase (hST8Sia I) gene expression in SK-MEL-2 human melanoma cells. Exp Mol Med (2010) 42(12):849-55. doi:10.3858/emm.2010.42.12.088
123. Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest (2012) 122(6):2066-78. doi:10.1172/JCI59735
124. Sarkar TR, Battula VL, Werden SJ, Vijay GV, Ramirez-Peña EQ, Taube JH, et al. GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene (2015) 34(23):2958-67. doi:10.1038/onc.2014.245
125. Zhu J, Wan Q, Lee D, Yang G, Spassova MK, Ouerfelli O, et al. From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine. J Am Chem Soc (2009) 131(26):9298-303. doi:10.1021/ja901415s
126. Vázquez AM, Gabri MR, Hernández AM, Alonso DF, Beausoleil I, Gomez DE, et al. Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol Rep (2000) 7(4):751-6. doi:10.3892/or.7.4.751
127. Alfonso M, Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol (2002) 168(5):2523-9. doi:10.4049/jimmunol.168.5.2523
128. Vázquez AM, Alfonso M, Lanne B, Karlsson KA, Carr A, Barroso O, et al. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma (1995) 14(6):551-6. doi:10.1089/hyb.1995.14.551
129. van Cruijsen H, Ruiz MG, van der Valk P, de Gruijl TD, Giaccone G. Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer (2009) 9:180. doi:10.1186/1471-2407-9-180
130. Torbidoni AV, Scursoni A, Camarero S, Segatori V, Gabri M, Alonso D, et al. Immunoreactivity of the 14F7 Mab raised against N-glycolyl GM3 ganglioside in retinoblastoma tumours. Acta Ophthalmol (2015) 93(4):e294-300. doi:10.1111/aos.12578
131. Lahera T, Calvo A, Torres G, Rengifo CE, Quintero S, Arango Mdel C, et al. Prognostic role of 14F7 Mab immunoreactivity against N-glycolyl GM3 ganglioside in colon cancer. J Oncol (2014) 2014:482301. doi:10.1155/2014/482301
132. Cacciavillano W, Sampor C, Venier C, Gabri MR, de Dávila MT, Galluzzo ML, et al. A phase I study of the anti-idiotype vaccine racotumomab in neuroblastoma and other pediatric refractory malignancies. Pediatr Blood Cancer (2015) 62(12):2120-4. doi:10.1002/pbc.25631
133. Hernández AM, Toledo D, Martínez D, Griñán T, Brito V, Macías A, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol (2008) 181(9):6625-34. doi:10.4049/jimmunol.181.9.6625
134. Vázquez AM, Hernández AM, Macías A, Montero E, Gómez DE, Alonso DF, et al. Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides-preclinical and clinical data. Front Oncol (2012) 2:150. doi:10.3389/fonc.2012.00150
135. Brändlein S, Pohle T, RuoffN, Wozniak E, Müller-Hermelink HK, Vollmers HP. Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res (2003) 63(22):7995-8005.
136. Lacombe J, Mangé A, Jarlier M, Bascoul-Mollevi C, Rouanet P, Lamy PJ, et al. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. Int J Cancer (2013) 132(5):1105-13. doi:10.1002/ijc.27766
137. Schneider C, Smith DF, Cummings RD, Boligan KF, Hamilton RG, Bochner BS, et al. The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Sci Transl Med (2015) 7(269):269ra1. doi:10.1126/scitranslmed.3010524
138. Rodriguez-Zhurbenko N, Rabade-Chediak M, Martinez D, Griñan T, Hernandez AM. Anti-NeuGcGM3 reactivity: a possible role of natural antibodies and B-1 cells in tumor immunosurveillance. Ann N Y Acad Sci (2015) 1362(1):224-38. doi:10.1111/nyas.12827
139. Rodríguez-Zhurbenko N, Martínez D, Blanco R, Rondón T, Griñán T, Hernández AM. Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties. Eur J Immunol (2013) 43(3):826-37. doi:10.1002/eji.201242693
140. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 15(17):5323-37. doi:10.1158/1078-0432.CCR-09-0737
141. Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clin Cancer Res (2012) 18(10):2740-53. doi:10.1158/1078-0432.CCR-11-1939
142. Parsons K, Bernhardt B, Strickland B. Targeted immunotherapy for high-risk neuroblastoma-the role of monoclonal antibodies. Ann Pharmacother (2013) 47(2):210-8. doi:10.1345/aph.1R353
143. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 14(11):1264-70. doi:10.1038/nm.1882
144. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 118(23):6050-6. doi:10.1182/blood-2011-05-354449
145. Liu Y, Wondimu A, Yan S, Bobb D, Ladisch S. Tumor gangliosides accelerate murine tumor angiogenesis. Angiogenesis (2014) 17(3):563-71. doi:10.1007/s10456-013-9403-4
146. Guerrera M, Ladisch S. N-butyldeoxynojirimycin inhibits murine melanoma cell ganglioside metabolism and delays tumor onset. Cancer Lett (2003) 201(1):31-40. doi:10.1016/S0304-3835(03)00459-2
147. Hudak JE, Bertozzi CR. Glycotherapy: new advances inspire a reemergence of glycans in medicine. Chem Biol (2014) 21(1):16-37. doi:10.1016/j.chembiol.2013.09.010
148. Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 98(6):3270-5. doi:10.1073/pnas.051626298
149. Huang YL, Hung JT, Cheung SK, Lee HY, Chu KC, Li ST, et al. Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer. Proc Natl Acad Sci U S A (2013) 110(7):2517-22. doi:10.1073/pnas.1222649110
150. Qiu L, Gong X, Wang Q, Li J, Hu H, Wu Q, et al. Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy. Cancer Immunol Immunother (2012) 61(11):2045-54. doi:10.1007/s00262-012-1224-6
151. Wang Q, Zhang J, Guo Z. Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell. Bioorg Med Chem (2007) 15(24):7561-7. doi:10.1016/j.bmc.2007.09.005
152. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer (2015) 15(6):361-70. doi:10.1038/nrc3930
153. Pearce OM, Läubli H, Verhagen A, Secrest P, Zhang J, Varki NM, et al. Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci U S A (2014) 111(16):5998-6003. doi:10.1073/pnas.1209067111